Press releasePRNewswire
Acurx Pharmaceuticals
ACXP · NASDAQ
$1.14+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.14
Latest news
- News
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
- Press releasePRNewswire
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releasePRNewswire
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
- Press releasePRNewswire
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
- Press releasePRNewswire
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
- Press releasePRNewswire
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
- Press releasePRNewswire
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
- Press releasePRNewswire
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
- Press releasePRNewswire
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
- Press releasePRNewswire
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
- Press releasePRNewswire
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
- Press releasePRNewswire
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
- Press releasePRNewswire
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
- Press releasePRNewswire
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
- Press releasePRNewswire
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- NewsAvi Kapoor
Crude Oil Gains Over 2%; PepsiCo Posts Upbeat Q1 Earnings
- NewsAvi Kapoor
Dow Surges Over 100 Points; US Initial Jobless Claims Fall
- Press releasePRNewswire
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Press releasePRNewswire
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsNabaparna Bhattacharya
What's Going On With Acurx Pharmaceuticals Stock Today?
- News
Earnings Scheduled For March 13, 2026
- Press releasePRNewswire
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsKaustubh Bagalkote
Why Is Acurx Pharmaceuticals Stock Falling Thursday?
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- NewsHenry Khederian
Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
- Press releasePRNewswire
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
- Press releasePRNewswire
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
- Press releasePRNewswire
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
- Press releasePRNewswire
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
- Press releasePRNewswire
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
- NewsAvi Kapoor
Crude Oil Rises Sharply; Jabil Earnings Top Views
- NewsAvi Kapoor
US Stocks Lower; Retail Sales Decline In May
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.